While FDA Tests CBD, the Industry Struggles for Consistency
In a test of 200 CBD products the Food and Drug Administration (FDA) found many contained CBD levels inconsistent with their labels — though not explicitly unsafe. The overall variability points (again) to what brands, researchers and advocacy organizations say is the bigger problem: lack of regulation in the budding industry.
The sample study, submitted to Congress earlier this month, tested 102 tinctures, capsules, edibles and beverages and pet products, that listed the amount of CBD on their labels. The test found that 45 percent contained within 20 percent of the stated level.